undamentalytics Newsletter
Sign in

Fate Therapeutics Inc balance sheet

At the end of fiscal 2025, Fate Therapeutics Inc had total assets of $319m and shareholders' equity of $207m. It held $46.6m in cash against $0 of debt: net cash of $46.6m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents69546589891911001671346142364732
Receivables——————1—69382411
Total current assets—10556693103205227494633502332292209158
Total assets—11566895105213302622921706506441319260
Accounts payable—11112466985933
Deferred revenue (current)—0—222832121421000
Total current liabilities—551315112728868111439393633
Short-term debt—2288—2————————
Long-term debt—221131512————————
Total debt04222131918140000000
Shareholders' equity−51−5351387377160245384679484368319207153
Net debt (negative = net cash)−6−5−52−43−76−70−172−86−167−134−61−42−36−47−32
Shares outstanding—1m—29m——65m76m88m96m97m99m114m115m117m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: FATE vs HCWBCGON vs FATEFATE vs TCRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Fate Therapeutics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Fate Therapeutics Inc.